Q97859249

Summary

Q97859249 is an individual motion^[1].

Key Facts

• Q97859249 authored Jan Lindholm^[2].
• Q97859249's instance of is recorded as individual motion^[3].
• Q97859249's part of the series is recorded as motions of the 2005-2006 legislative session of the Riksdag^[4].
• Q97859249's language of work or name is recorded as Swedish^[5].
• Q97859249's publication date is recorded as +2005-09-29T00:00:00Z^[6].
• Q97859249's main subject is recorded as medication^[7].
• Q97859249's main subject is recorded as Swedish Medical Products Agency^[8].
• Q97859249's work available at URL is recorded as http://data.riksdagen.se/dokument/GT02So382^[9].
• Q97859249's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/GT02So382^[10].
• Q97859249's applies to jurisdiction is recorded as Sweden^[11].
• Q97859249's legal citation of this text is recorded as Mot. 2005/06:So382^[12].
• Q97859249's title is recorded as Ändrad finansieringsform för Läkemedelsverket^[13].
• Q97859249's maintained by WikiProject is recorded as Project Riksdagen's documents^[14].
• Q97859249's copyright status is recorded as public domain^[15].
• Q97859249's legislative committee is recorded as Committee on Health and Welfare^[16].
• Q97859249's Swedish Riksdag document ID is recorded as GT02So382^[17].

Body

Works and Contributions

Q97859249 authored Jan Lindholm^[2].